©The Author(s) 2025.
World J Gastroenterol. Nov 7, 2025; 31(41): 111449
Published online Nov 7, 2025. doi: 10.3748/wjg.v31.i41.111449
Published online Nov 7, 2025. doi: 10.3748/wjg.v31.i41.111449
Table 3 Comparison of laboratory test indicators between autoimmune gastritis patients with or without gastric neuroendocrine tumors, n (%)/mean ± SD/median (interquartile range)
| Variables | Total (n = 303) | Non-gNETs group (n = 187) | gNETs group (n = 116) | P value | Missing |
| PCA | 0.019a | 9 (2.97) | |||
| Positive (≥ 1:160) | 144 (48.8) | 89 (49.7) | 55 (47.4) | ||
| Weak positive (1:100) | 129 (43.7) | 71 (39.7) | 58 (50) | ||
| Negative (< 1:100) | 22 (7.5) | 19 (10.6) | 3 (2.6) | ||
| IFAb (AU/mL) | 0.572 | 11 (3.63) | |||
| Positive (≥ 1.53) | 135 (46.2) | 85 (47.5) | 50 (44.2) | ||
| Weak positive (1.2-1.53) | 63 (21.6) | 35 (19.6) | 28 (24.8) | ||
| Negative (< 1.2) | 94 (32.2) | 59 (33) | 35 (31) | ||
| Gastrin-17 (pmol/L) | 51.3 (6.9, 64.4) | 55.3 (40.0, 71.4) | 49.8 (35.3, 62.1) | 0.257 | 229 (75.58) |
| Vitamin B12 (pmol/L) | < 0.001b | 22 (7.26) | |||
| ≤ 133 | 184 (64.3) | 96 (55.8) | 88 (77.2) | ||
| 133-223 | 41 (14.3) | 27 (15.7) | 14 (12.3) | ||
| > 223 | 61 (21.3) | 49 (28.5) | 12 (10.5) | ||
| TPOAb or TGAb positive | 111 (51.9) | 52 (50) | 59 (53.6) | 0.595 | 89 (29.37) |
| Other antibody positive | 50 (17.0) | 37 (20.6) | 13 (11.4) | 0.042a | 9 (2.97) |
| IFAb (AU/mL) | 1.3 (1.2, 32.8) | 1.3 (1.2, 57.5) | 1.3 (1.2, 11.5) | 0.257 | 11 (3.63) |
| Vitamin B12 (pmol/L) | 124.0 (80.0, 221.0) | 152.0 (83.0, 275.0) | 102.0 (79.5, 151.2) | < 0.001b | 22 (7.26) |
| Ferritin (ng/mL) | 23.1 (9.2, 63.4) | 30.6 (9.1, 68.8) | 19.6 (9.2, 39.6) | 0.077 | 23 (7.59) |
| WBC (× 109/L) | 5.5 ± 1.6 | 5.7 ± 1.6 | 5.3 ± 1.4 | 0.035a | 15 (4.95) |
| HGB (g/L) | 125.1 ± 25.1 | 122.1 ± 25.9 | 129.6 ± 23.2 | 0.012a | 9 (2.97) |
| MCV (fL) | 87.7 ± 10.4 | 88.3 ± 11.9 | 86.8 ± 7.6 | 0.208 | 13 (4.29) |
| PLT (× 109/L) | 224.3 ± 71.2 | 228.0 ± 75.2 | 218.9 ± 64.9 | 0.292 | 18 (5.94) |
| PGI (ng/mL) | 5.9 (3.5, 9.6) | 7.4 (4.3, 16.3) | 4.3 (3.0, 7.0) | < 0.001b | 110 (36.30) |
| PGI/II | 0.8 (0.6, 1.2) | 1.1 (0.6, 1.6) | 0.7 (0.5, 0.9) | < 0.001b | 112 (36.96) |
| TSH (μIU/mL) | 2.1 (1.3, 3.4) | 2.1 (1.5, 3.7) | 2.1 (1.3, 3.1) | 0.227 | 86 (28.38) |
| TPOAb (IU/mL) | 26.2 (9.9, 258.0) | 20.0 (9.4, 166.0) | 53.2 (10.2, 357.8) | 0.167 | 90 (29.70) |
| TGAb (IU/mL) | 24.9 (14.7, 102.8) | 23.1 (14.1, 59.7) | 25.0 (15.0, 163.2) | 0.191 | 89 (29.37) |
| HCY (μmol/L) | 11.3 (9.1, 15.8) | 12.3 (9.1, 17.5) | 11.2 (9.1, 14.3) | 0.142 | 149 (49.17) |
- Citation: Li YM, Guo WJ, Deng C, Luo J, Shi YF, Zhu D, Wei QL, Zhang MG, Du SY, Tan HY. Risk assessment of type I gastric neuroendocrine tumors based on endoscopic and clinical features of autoimmune gastritis. World J Gastroenterol 2025; 31(41): 111449
- URL: https://www.wjgnet.com/1007-9327/full/v31/i41/111449.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i41.111449